查看文章

Background. Adding taxanes to anthracycline‐based adjuvant chemotherapy has shown significant improvement particularly in node‐positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose‐dense epirubicin and cyclophosphamide followed by docetaxel in node‐positive breast cancer. Methods. All Patients first received 4 cycles of epirubicin (100 mg/m²) and cyclophosphamide (600 mg/m²) at 2‐week interval then followed by docetaxel (100 mg/m²) at 2‐week interval for 4 cycles, with daily Pegfilgrastim (G‐CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion. Results. Fifty‐eight patients with axillary lymph node‐positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity‐related deaths, one patient due to grade …